Home › Trial NCT01432483
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
- Trial IDNCT01432483
- StatusUnknown
- PhaseN/A
- Study typeExpanded_Access
- SponsorEisai Inc.
- Enrollment—
- Start date—
- ConditionsCancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.